Clinical description of patients after exposure to MMR/V
| Patient . | P1 . | P2 . | P3 . | P4 . | P5 . | P6 . | P7 . |
|---|---|---|---|---|---|---|---|
| Kindred | A | A | B | C | C | D | E |
| Age at presentation (mo) | 12 | 12 | 15 | 13 | 16 | 14 | NA |
| Age at diagnosis of IFNAR1 deficiency | –a | –a | 17 mo | 13 mo | 7 yr | 4 yr | 13 yr |
| Level of care (post-exposure onset day)b | |||||||
| Hospitalization, secondary | 5 | 2 | 11 | NA | NA | 25 | NA |
| Hospitalization, tertiary | 14 | NA | 60 | 10 | 17 | NA | NA |
| Hospitalization, PICU | 14 | NA | 60 | 14 | NA | NA | NA |
| Clinical presentation (post-exposure onset day)b | |||||||
| Localized injection site reaction | 5 | NR | NR | 10 | NR | NR | NA |
| Acute neurological clinical manifestations | 10 | Y | 11 | 14 | Y | 25 | NA |
| Acute hyperinflammation | 14 | Y | 17 | 14 | Y | NR | NA |
| Acute respiratory clinical manifestations | 15 | Y | 62 | 14 | N | NR | NA |
| Death | 18 | 21 | 72 | NAc | NA | NA | NA |
| Other | NA | NA | Knee + ankle joint effusions, day 24 | NA | NA | NA | NA |
| Other clinical features | |||||||
| Infections and comorbidities before dose 1 of MMR/V vaccination | NA | NA | EV meningitis; CNS structural anomalies | Premature birth (24 wk gestation), CLD, IVH, 2× bronchiolitis admissions <7 d | Tetralogy of Fallot (repaired at age 6 mo), 4× bronchiolitis admissions <7 d | NA | Hib sepsis/meningitis; RSV LRTI |
| Infections diagnosed after dose 1 of MMR/V vaccination | NA | NA | NA | Fatal RSV ARDS (+4 mo) | EV meningitis (+8 mo); RSV LRTI (+9 mo) | RSV, HPIV-3, RV, Bocavirus LRTI, ECMO (+9 mo) | LRTI, HFOV |
| Patient . | P1 . | P2 . | P3 . | P4 . | P5 . | P6 . | P7 . |
|---|---|---|---|---|---|---|---|
| Kindred | A | A | B | C | C | D | E |
| Age at presentation (mo) | 12 | 12 | 15 | 13 | 16 | 14 | NA |
| Age at diagnosis of IFNAR1 deficiency | –a | –a | 17 mo | 13 mo | 7 yr | 4 yr | 13 yr |
| Level of care (post-exposure onset day)b | |||||||
| Hospitalization, secondary | 5 | 2 | 11 | NA | NA | 25 | NA |
| Hospitalization, tertiary | 14 | NA | 60 | 10 | 17 | NA | NA |
| Hospitalization, PICU | 14 | NA | 60 | 14 | NA | NA | NA |
| Clinical presentation (post-exposure onset day)b | |||||||
| Localized injection site reaction | 5 | NR | NR | 10 | NR | NR | NA |
| Acute neurological clinical manifestations | 10 | Y | 11 | 14 | Y | 25 | NA |
| Acute hyperinflammation | 14 | Y | 17 | 14 | Y | NR | NA |
| Acute respiratory clinical manifestations | 15 | Y | 62 | 14 | N | NR | NA |
| Death | 18 | 21 | 72 | NAc | NA | NA | NA |
| Other | NA | NA | Knee + ankle joint effusions, day 24 | NA | NA | NA | NA |
| Other clinical features | |||||||
| Infections and comorbidities before dose 1 of MMR/V vaccination | NA | NA | EV meningitis; CNS structural anomalies | Premature birth (24 wk gestation), CLD, IVH, 2× bronchiolitis admissions <7 d | Tetralogy of Fallot (repaired at age 6 mo), 4× bronchiolitis admissions <7 d | NA | Hib sepsis/meningitis; RSV LRTI |
| Infections diagnosed after dose 1 of MMR/V vaccination | NA | NA | NA | Fatal RSV ARDS (+4 mo) | EV meningitis (+8 mo); RSV LRTI (+9 mo) | RSV, HPIV-3, RV, Bocavirus LRTI, ECMO (+9 mo) | LRTI, HFOV |
ARDS, acute respiratory distress syndrome; CLD, chronic lung disease; day 1, day of exposure to LAV; HFOV, high-frequency oscillatory ventilation; IVH, intraventricular hemorrhage; LRTI, lower respiratory tract infection; N, no; NA, not applicable; NR, not reported; Y, yes.
Diagnosed postmortem.
MMR administered on day 1.
Died from ARDS due to RSV 4 mo later.